New treatment modalities for obesity

Best Pract Res Clin Endocrinol Metab. 2018 Aug;32(4):535-549. doi: 10.1016/j.beem.2018.06.007. Epub 2018 Jun 25.

Abstract

The treatment of childhood obesity represents a greater challenge for pediatricians. To date, it is multidisciplinary, including behavioral, dietary, pharmacological, and surgical options. Given the limited efficacy of available treatments, scientific research on finding new solutions is very active. Several drugs comprising Metformin, Glucagon-like peptide- 1 receptor agonists, Naltrexone-bupropion, Phentermine-Topiramate, and Lorcaserin have been studied as pediatric antiobesity agents. Findings from clinical trials showed a modest but significant effect of these drugs on weight loss, but long-term studies are needed to better define their exact role. Bariatric surgery is also promising for extremely obese adolescents. Moreover, a novel approach to treat obesity might be represented by compounds inducing browning of white adipose tissue, a complex process involved in body energy homeostasis, but at present evidence in humans is lacking. We aimed to review the current knowledge regarding the available new options for pediatric obesity treatment.

Keywords: adolescent; bariatric surgery; children; obesity; pharmacotherapy.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Anti-Obesity Agents / therapeutic use*
  • Bariatric Surgery*
  • Benzazepines / therapeutic use
  • Child
  • Diet
  • Humans
  • Naltrexone / therapeutic use
  • Pediatric Obesity / drug therapy
  • Pediatric Obesity / surgery
  • Pediatric Obesity / therapy*
  • Weight Loss

Substances

  • Anti-Obesity Agents
  • Benzazepines
  • Naltrexone
  • lorcaserin